Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Apr 11;66(7):1950–1956. doi: 10.2337/db16-1035

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.

PMC Copyright notice

RUNX1 inhibition reduces neovascularization in the OIR model. A: Retina of P17 C57BL/6J mice with OIR costained for RUNX1 and vessels (IB4 or CD31) showing positive RUNX1 staining conforming to neovascular tufts (arrows) and not to normal underlying vasculature. Scale bars = 50 μm. B: Retinal flat mounts of P17 C57BL/6J mice following OIR induction and intravitreal injection of 75 μmol/L Ro5–3335 or vehicle at P13 and P15 (red overlay identifies the avascular area and neovascularization, respectively). Scale bars = 1 mm. There was a nonsignificant downward trend in avascular area but a significant reduction in neovascularization in the treated group compared with vehicle-treated group (n_vehicle = 7; n_Ro5–3335 = 9). Experiment performed in triplicate. **P < 0.01.